Biopharmaceutical scientists proactively search for technologies that adapt to their evolving requirements when creating new, more effective treatments for diseases. This helps ensure the safety, efficacy and commercial viability of the final biologic or biosimilar.
RedShiftBio’s Microfluidic Modulation Spectroscopy (MMS) analytical technique enables scientists to “see change” in a protein’s structure faster and more efficiently than ever before. MMS combines the high energy of a laser with microfluidic flow technologies.
RedShiftBio will launch its first MMS enabled instrument in 2018. The instrument will feature an innovative, powerful and flexible bioanalytics software package to both automate the routine day to day analysis of spectroscopic data and to provide tools for gaining new insights into biophysical structure changes.
Microfluidic Modulation Spectroscopy is ideally suited for biophysical and secondary structure characterization of proteins and will:
- Provide greater ability to “see change” through dramatic improvements in resolution and sensitivity
- Perform 5 key measurements on a single system and from a single sample or family of related samples (Aggregation, Quantitation, Stability, Similarity, Structure)
- Measure over the widest concentration ranges - 0.1 to greater than 200mg/mL
- Features walk away, multi-sample capability
How well does MMS work? The accuracy, repeatability and reliability of MMS has been verified across thousands of protein measurements and through comparisons to established databases. Hundreds of samples have been run with collaborators from industry and academia with impressive results – results that will start to be published in 2018. Contact us if you would like to ‘see change’ in your samples.
RedShift™, RedShiftBio™, and See Change™ are trademarks of RedShift BioAnalytics, Inc.